Fundraising Fox

PHARMAIN CORPORATION

Bothell, US · Founded 2000 · 25 employees on LinkedIn

PharmaIN is a clinical-stage biopharmaceutical company developing peptide-based, subcutaneous self-injectable therapies through peptide engineering and drug delivery. Its pipeline targets advanced liver cirrhosis and cancer, including PHIN-214, a vasopressor therapy for decompensated cirrhosis in Phase 1 trials.

BiotechHealthtech

Founders & leadership

PHARMAIN CORPORATION was founded in 2000 by Elijah Bolotin.

EB
Elijah BolotinFounder

Board

JP
John PresuttiBoard director
JF
James FoghtBoard director
LS
Lester SalansBoard director
TP
Tibor PappBoard director

Reported raises · per SEC filings

Form D private placements

$1.5M disclosed across 1 round · 2014

▶$1.5MraisedMay 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PresuttiDirector
  • James FoghtDirector
  • Elijah BolotinExecutive Officer, Director
  • Lester SalansDirector
  • Tibor PappDirector
Offering amount
$5M
Amount sold
$1.5M
First sale
Apr 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 20 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$995.1K
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$967.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$1000K
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$599.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$573.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$225K
National Institutes of Health (NIH)National Institutes of HealthPhase II2013$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$600K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$372.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$599.9K
National Institutes of Health (NIH)National Institutes of HealthPhase II2010$782.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$223.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$160.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$600K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$443.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2008$383.6K
National Institutes of Health (NIH)National Institutes of HealthPhase II2007$914.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$1M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does PHARMAIN CORPORATION do?
PharmaIN is a clinical-stage biopharmaceutical company developing peptide-based, subcutaneous self-injectable therapies through peptide engineering and drug delivery. Its pipeline targets advanced liver cirrhosis and cancer, including PHIN-214, a vasopressor therapy for decompensated cirrhosis in Phase 1 trials.
Who founded PHARMAIN CORPORATION?
PHARMAIN CORPORATION was founded by Elijah Bolotin in 2000.
How much funding has PHARMAIN CORPORATION raised?
PHARMAIN CORPORATION has disclosed $1.5M raised across 1 round.
Where is PHARMAIN CORPORATION headquartered?
PHARMAIN CORPORATION is headquartered in Bothell, US.